Tag: mRNA
H5N1 causes neurological issues, India could offer a potential mRNA vaccine:...
Dr Praveen Gupta, Principal Director and Chief of Neurology, Fortis Hospital said that early recognition and management of these complications are crucial, as they can significantly impact the prognosis and outcomes
CIPLA EU to invest an additional EUR 3 million in Ethris
This additional investment through a convertible loan will accelerate Cipla’s participation in the mRNA space
Moderna receives U.S. FDA approval for RSV Vaccine mRESVIA
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
Medicine has to be practiced as a team science: Prof....
Former President of the Public Health Foundation of India presented medical degrees to UG & PG students of Apollo Medical College
Nobel Prize for scientists whose research was critical to develop mRNA...
The Nobel Prize in Physiology or Medicine 2023 was awarded jointly to Katalin Karikó and Drew Weissman for their discoveries concerning nucleoside base modifications
India’s first mRNA based Omicron-specific booster vaccine from Gennova gets DCGI...
The Omicron specific mRNA vaccine will be available under the name - GEMCOVAC®-OM. The intradermal vaccine is stable at 2-8 °C and is administered using a needle-free device
Merck Study: mRNA technology a ‘Game Changer’ for Asia-Pacific vaccine manufacturers
More than 60% vaccine makers surveyed plan revamp or new facilities for mRNA manufacturing to meet demand
Ultragenyx’s UX053 Phase I/II study termination a minor setback for mRNA...
The study was terminated due to reasons unrelated to safety concerns, although the specific rationale has not been disclosed by the biopharmaceutical company
BioAsia 2023 confers Genome Valley Excellence Award upon Professor Robert S....
Langer, the David H. Koch Institute Professor at MIT and co-founder of Moderna, is awarded for his pioneering research work that led to the commericialization of mRNA vaccine
Cipla & Ethris partner for the development of mRNA-based therapies
The definitive agreements for equity investment of EUR 15 million in Ethris GmbH will fast-track Cipla’s participation in the mRNA space